

Low penetrance breast cancer susceptibility genes

P. Devilee

Leiden University Medical Centre, Leiden, The Netherlands.

Approximately 13% of all breast cancer patients have one or more first-degree relatives with breast cancer [1]. The overall relative risk for a first-degree relative to develop breast cancer herself (also termed excess familial risk) is about 1.80. A major question is how much of this risk is determined by genetic factors. A large Scandinavian twin study [2] indicated that 27% of the variance in susceptibility was due to heritable factors. How many genes underlie this susceptibility is as yet unknown. Peto and Mack looked at breast cancer incidence data in monozygotic twins, the contralateral breast and in first-degree relatives of patients [3]. They observed that patients with breast cancer are at a very high risk of developing another cancer in the other breast and that this risk does not change with the age of the first cancer, being about 0.7% per year. They argue that most of this high risk is genetic because a similar pattern is seen in monozygotic twins, where the risk is about twice the contralateral breast cancer risk of any individual, which is consistent given that in the latter case only one breast is at risk. In keeping with this model, risk in first-degree relatives of breast cancer patients is about one-quarter that of monozygotic twins. The inference of their model is that the first cancer (i.e., breast cancers in the population as a whole) occurs in a minority of women who are susceptible for it.

A more conventional model of inherited breast cancer susceptibility is that disease risks are affected by mutations in a small number of genes causing a high risk of the disease, and also a larger number of lower risk gene variants probably interacting together [4]. The nineties of the past century have witnessed the identification of several high-risk breast cancer susceptibility genes, mostly by model-based linkage analysis in multiple-case families followed by positional cloning. BRCA1 and BRCA2 are the most well known of these, and the cancer risks conferred by mutations in these genes are now well established [5]. It has been estimated that mutations in BRCA1 and BRCA2 explain less than 20% of the overall excess familial risk seen among unselected cases and their relatives. Several genetic models have been proposed to explain the residual familial risk, ranging from a rare dominant, moderately penetrant gene, to a common high penetrance recessive gene [6]. Even among families with multiple cases of early-onset breast cancer, certain types of familial clustering of breast cancer are unlikely to be due to BRCA1 or BRCA2 [7]. Thus, families with at least 4 cases of breast cancer and at least one case of ovarian cancer can be attributed largely to BRCA1. Multiple-case families with at least one case of male breast cancer are mainly due to BRCA2. But the majority of families with 4 or 5 cases of female breast cancer diagnosed before the age of 60 are not due to BRCA1 or BRCA2. This has been taken as evidence that one or more moderate to high-risk breast cancer susceptibility genes still remain to be identified. There have indeed been several linkage claims since BRCA1 and BRCA2 were identified, but none of these have been replicated in other, often larger studies. Examples are 8p22, a locus that seemed to be linked to breast cancer in a few families [8;9], but was excluded in a larger set [10], and 13q21 [11;12]. Most studies, however, are heavily underpowered to detect a new breast cancer locus by linkage in the presence of substantial genetic heterogeneity. If BRCA3 would cause familial breast cancer in only 25% of such families, over 300 families would be required to detect it by conventional linkage analysis. The Breast Cancer Linkage Consortium has recently compiled genome-wide linkage data on 149 families in which the role of BRCA1 or

BRCA2 has been excluded with >90% certainty[13]. This comprises the largest linkage search effort in the world to date. These families are characterised by the presence of at least 3 cases of breast cancer diagnosed before the age of 60, no cases of ovarian or male breast cancer. However, no significant linkage peaks were detected. The highest model-based lod score was 1.8 at the short arm of chromosome 4, while a maximum lod score of 2.40 on chromosome 2p was found in families with four or more cases of breast cancer diagnosed before age 50 years.

A model in which several common, low penetrance genes with multiplicative effects on risk could also account for the residual non-BRCA1/2 familial aggregation. The biggest immediate challenge now is to identify such genetic factors. Parametric linkage analysis in families is not feasible, and here one generally relies on some form of genetic association study. Genome-wide searches for association between genetic variation at >300,000 SNPs and disease susceptibility are now becoming feasible [14]. Previously, the study design most often opted for is one in which a functional variant in a candidate gene is selected, and its prevalence assayed in a population of cases and controls. The present state of this research area is characterised by many conflicting results. Whereas everybody agrees that genes involved in oestrogen biosynthesis and metabolism [15], DNA repair [16], apoptosis, and cell cycle control, are all good candidates for breast cancer risk factors, it is very often not clear what the functional relevance of genetic variation in these genes is. In addition, hidden population stratification may give rise to false-positive or false-negative results, and many association studies have in fact been conducted on too small populations [17]. Finally, there is a debate raging in the literature between proponents of a model which assumes that most disease susceptibility variants are common in the population (frequency >1%) versus those that assume that late-onset diseases are due to large numbers of rare variants at many loci [18]. Under the first model, common susceptibility alleles are potentially detectable in large-scale patient-control association studies, but under the last model, such a strategy would fail and the contribution of most individual variants would be too small to further our understanding of disease.

If all of the susceptibility factors could be identified, it would in principle be possible to identify women as susceptible for breast cancer by their genotypic profile, opening up avenues for targeted breast cancer prevention [19]. However, population-based gene testing for breast cancer will never become acceptable in the absence of a cost-effective, non-invasive preventive intervention.

Reference List

- (1) Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 women without the disease. *Lancet* 2001; 358(9291):1389-1399.
- (2) Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000; 343(2):78-85.
- (3) Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. *Nature Genet* 2000; 26:411-414.
- (4) Antoniou AC, Pharoah PDP, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF. A comprehensive model for familial breast cancer

incorporating BRCA1, BRCA2 and other genes. *Br J Cancer* 2002; 86(1):76-83.

- (5) Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton CH, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. *Am J Hum Genet* 2003; 72(5):1117-1130.
- (6) Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, Giles GG, McCredie MR, Hopper JL. After BRCA1 and BRCA2-What Next? Multifactorial Segregation Analyses of Three-Generation, Population-Based Australian Families Affected by Female Breast Cancer. *Am J Hum Genet* 2001; 68(2):420-431.
- (7) Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M, Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *Am J Hum Genet* 1998; 62(3):676-689.
- (8) Kerangueven F, Essioux L, Dib A, Noguchi T, Allione F, Geneix J, Longy M, Lidereau R, Eisinger F, Pébusque M-J, Jacquemier J, Bonaïti-Pellié C, Sobol H, Birnbaum D. Loss of heterozygosity and linkage analysis in breast carcinoma: Indication for a putative third susceptibility gene on the short arm of chromosome 8. *Oncogene* 1995; 10:1023-1026.
- (9) Seitz S, Rohde K, Bender E, Nothnagel A, Kolble K, Schlag PM, Scherneck S. Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. *Oncogene* 1997; 14(6):741-743.
- (10) Rahman N, Teare MD, Seal S, Renard H, Mangion J, Cour C, Thompson D, Shugart Y, Eccles D, Devilee P, Meijers H, Nathanson KL, Neuhausen SL, Weber B, Changclaude J, Easton DF, Goldgar D, Stratton MR. Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. *Oncogene* 2000; 19:4170-4173.
- (11) Kainu T, Joo SH, Desper R, Schaffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi OP, Tirkkonen M, Syrjakoski K, Kuukasjarvi T, Koivisto P, Karhu R, Holli K, Arason A, Johannesdottir G, Bergthorsson JT, Johannsdottir H, Egilsson V, Barkardottir RB, Johannsson O, Haraldsson K, Sandberg T, Holmberg E, Gronberg H, Olsson H, Borg A, Vehmanen P, Eerola H, Heikkila P, Pyrhonen S, Nevanlinna H. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. *Proc Natl Acad Sci USA* 2000; 97(17):9603-9608.

- (12) Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze JK, Teare D, Rahman N, Renard H, Mann G, Hopper JL, Buys SS, Andrulis IL, Senie R, Daly MB, West D, Ostrander EA, Offit K, Peretz T, Osorio A, Benitez J, Nathanson KL, Sinilnikova OM, Olah E, Bignon YJ, Ruiz P, Badzioch MD, Vasen HFA, Futreal AP, Phelan CM, Narod SA, Lynch HT, Ponder BAJ, Eeles RA, Meijers HH, Stoppa LD, Couch FJ, Eccles DM, Evans DG, Chang CJ, Lenoir G, Weber BL, Devilee P, Easton DF, Goldgar DE, Stratton MR. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. *Proc Natl Acad Sci USA* 2002; 99(2):827-831.
- (13) Smith P, McGuffog L, Easton DF, Breast Cancer Linkage Consortium. A genome wide linkage search for breast cancer susceptibility genes. *Genes Chrom Cancer*. In press.
- (14) Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. *Nat Rev Cancer* 2004; 4(11):850-860.
- (15) Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer - The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. *Mutation Research Reviews in Mutation Research* 2003; 544(1):9-41.
- (16) Mohrenweiser HW, Wilson DM, Jones IM. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. *Mutation Research Fundamental and Molecular Mechanisms of Mutagenesis* 2003; 526(1-2):93-125.
- (17) Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: Implications for design of association studies. *Genet Epidemiol* 2003; 25(3):190-202.
- (18) Weiss KM, Terwilliger JD. How many diseases does it take to map a gene with SNPs? *Nat Genet* 2000; 26(2):151-157.
- (19) Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ. Polygenic susceptibility to breast cancer and implications for prevention. *Nature Genet* 2002; 31(1):33-36.